搜索
>产品 > Anti-CD20 (Rituximab) CAR

专用于检测Anti-CD20 (Rituximab) CAR的高特异性抗体

抗体特性经Flow Cytometry验证并免费提供Protocol

背景
CD20因其在B淋巴细胞发育阶段的表达特点被选定为治疗B细胞淋巴瘤和白血病的重要靶点之一,也是CAR-T研究领域的热门靶点。Rituximab是1997年FDA批准的全球第一个靶向CD20用于治疗B细胞非霍奇金淋巴瘤的单克隆抗体,是迄今商业化最成功的CD20单抗药物。根据2018年中检院颁布的《CAR-T细胞治疗产品质量控制检测研究及非临床研究考虑要点》,CAR转染阳性率的检测应采用流式细胞法,推荐使用具有更好专属性的针对抗原结合部位的抗原蛋白或抗独特型抗体进行检测。
在实际检测中,抗独特型抗体(anti-idiotypic antibody)相对抗原来说具有更高的灵敏度和更好的特异性,是检测CAR表达更为理想的工具。ACROBiosystems开发的Anti-Rituximab Monoclonal Antibodies能够特异性的识别Rituximab的抗原识别位点,具有特异性强、灵敏度高的特点,经充分验证可适用于Flow Cytometry (FCM)方法检测Anti-CD20 (Rituximab) CAR的表达,ACRO可免费提供经验证的Protocol。
产品列表
Molecule Cat. No. Species Source Product Description
Rituximab RIB-Y35 Mouse Hybridoma Anti-Rituximab Antibodies
产品特点
适用于FCM法检测Anti-CD20 (Rituximab) CAR的表达
Evaluation of Anti-CD20 (Rituximab) Expression by FCM
2×105 Anti-CD20 (Rituximab)-CAR 293 cells were first stained with anti-rituximab antibody (mouse IgG1, Cat. No. RIB-Y35) and followed by incubation with PE-labeled anti-mouse IgG1 antibody. PE-labeled anti-mouse IgG1 antibody was used as a negative control.

Protocol

能够特异性的识别Rituximab的抗原识别位点
Neutralizing activity measured by FCM

Flow Cytometry analysis shows that the binding of rituximab to 293F overexpressing CD20 was inhibited by increasing concentration of anti-rituximab antibodies (Cat. No. RIB-Y35). The concentration of rituximab used is 10 ng/ml. The IC50 is 0.013 μg/ml.

Protocol

High affinity determined by SPR

Anti-rituximab antibodies (mouse IgG1, Cat. No. RIB-Y35) captured on CM5 chip via anti-mouse antibodies surface, can bind rituximab with an affinity constant of 0.03 nM.

Protocol

*如果您希望ACRO开发更多类型的Anti-Rituximab Antibodies产品, 请 点击提议
*如果您希望ACRO补充更多Anti-Rituximab Antibodies产品的实验设计和应用数据,请 点击咨询

消息提示

请输入您的联系方式,再点击提交!

确定